Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-3 trial of tavapadon adjunctive therapy in levodopa-treated Parkinson's disease with motor fluctuations
2019-002951-40Phase 3Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Tavapadon adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change from baseline in total daily hours of on time without troublesome dyskinesia. Started Feb 2020; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-002951-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002951-40.